This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone quarter ended 30 September 2026: revenue down 1.2% year on year, profit Rs 131.92 lakh
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone quarter ended 30 September 2026: revenue from operations fell 1.2% to Rs 1,277.71 lakh from Rs 1,292.63 lakh a year earlier; profit after tax was Rs 131.92 lakh versus Rs 140.36 lakh. The operating margin before interest, tax, depreciation and amortisation fell to 13.0% from 14.6%. Half-year operating cash flow was positive at Rs 390.32 lakh. Prior-period figures were regrouped or reclassified; the review was unmodified.
Mildly negative: revenue, profit and operating margin declined, though positive half-year cash flow and an unmodified review offer support.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹12.78 Cr | ₹12.93 Cr | −1.2% |
| Operating profit | ₹1.51 Cr | ₹1.73 Cr | −12.4% |
| Profit after tax | ₹1.32 Cr | ₹1.40 Cr | −6.0% |
| EBITDA margin | 13.0% | 14.6% | −1.6 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.